Showing 3361-3370 of 5257 results for "".
- Patient-Centric Guidelines for Generalized Pustular Psoriasis Management Unveiledhttps://practicaldermatology.com/news/patient-centric-guidelines-for-generalized-pustular-psoriasis-management-unveiled/2471251/A global Delphi study has established holistic treatment goals for generalized pustular psoriasis (GPP), integrating both physician and patient perspectives. The consensus study included participants from 24 countries, and acc
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- 'Dr. Pimple Popper' Offers Social Media Advicehttps://practicaldermatology.com/news/Dr-Pimple-Popper-Offers-Social-Media-Advice/2471209/Social media transformed Sandra Lee, MD, FAAD, FAACS, into “Dr. Pimple Popper.” While not every dermatologist aspires to have their own television show, many would like to maximize the impact of their social media presence, and Dr. Lee shared pearls from her own experience at the Winter Clinical
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Hidradenitis Suppurativa Genetics Linked to Cardiometabolic Riskhttps://practicaldermatology.com/news/hidradenitis-suppurativa-genetics-linked-to-cardiometabolic-risk/2471117/A high polygenic risk score (PRS) for hidradenitis suppurativa (HS) is linked to an increased risk of coronary artery disease (CAD) and diabetes, according to a new analysis of UK Biobank data. Study researchers included 391,481 individuals of European ancestry with data in UK Biobank in t
- Galderma Renews Sensitive Skin Care Research Fund at GWhttps://practicaldermatology.com/news/galderma-renews-sensitive-skin-care-research-fund-at-gw/2471114/Galderma extended its partnership with the Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) by renewing the Sensitive Skin Care Research Acceleration Fund to support efforts to redefine the understanding and management of this
- Phase 1 Study Begins for New Systemic for CPUOhttps://practicaldermatology.com/news/Phase-1-Study-Begins-New-Systemic-CPUO/2471095/The first subject has been dosed in a first-in-human Phase 1 study of ATTO-1310, a novel, subcutaneous (SQ), half-life extended (HLE) anti-IL-31 biotherapeutic, Attovia Therapeutics announced. ATTO-1310 is being evaluated as a potential systemic treatment for people living with pruritic co